Alliance Pharma Regulatory News (APH)

12 Dec 2005 07:02

Alliance Pharma PLC12 December 2005 For immediate release 12 December 2005 ALLIANCE PHARMA PLC ("Alliance" or "the Company") Alliance Pharma to present at the London Biotech Investment Forum at the London Stock Exchange Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,announces that John Dawson, the Company's Chief Executive, will today make apresentation at the London Biotech Investment Forum, a one-day conference beingheld at the London Stock Exchange. Mr Dawson's presentation will focus on the Company's business model, in which astable of cash generative products provides the cash flow for investment in newopportunities, and on the Company's late stage portfolio, includingPosidorm(TM), the Company's new therapy for sleep disorders. A copy of the presentation will be available on the Company's website atwww.alliancepharma.co.uk For further information: Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000Mark Court/Lisa Baderoon/Rebecca Skye Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed emerging specialitypharmaceutical company based in Chippenham, Wiltshire, UK. The company has astrong track record of acquiring the rights to established niche brands andowns, or shares, the rights to 30 branded pharmaceutical products and continuesto explore opportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to pharmaceutical wholesalers whichservice both hospital and retail pharmacies with their prescriptionrequirements. Alliance Pharma is also developing novel products for sleep disorders and theinduction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange